Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Interchangeability: FDA Sets ‘Stringent’ Standard On Design Differences

Executive Summary

Sponsors must assess any differences in a biosimilar’s container closure system or delivery device relative to the US reference product and may need to conduct comparative use human factor studies to ensure there is no increased risk of use-related error with the biosimilar.

Advertisement

Related Content

Make Interchangeability Great Again: Biosimilar Switching Studies Need US Comparators
Biosimilar Interchangeability: How To Design A Multiple-Switch Study
Biosimilars: Postmarketing Data Alone Not Enough For Interchangeability
ANDAs For Drug/Device Combos Face High Bar At US FDA; Epipen, Advair May Benefit
Biosimilars' Pediatric Pressures Could Push Them Toward Interchangeability

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register